S&P 500   5,249.49 (+0.02%)
DOW   39,753.43 (-0.02%)
QQQ   444.26 (-0.13%)
AAPL   171.28 (-1.17%)
MSFT   420.06 (-0.33%)
META   486.26 (-1.54%)
GOOGL   150.72 (-0.10%)
AMZN   180.14 (+0.17%)
TSLA   177.42 (-1.34%)
NVDA   905.75 (+0.36%)
NIO   4.57 (-2.14%)
AMD   180.85 (+0.70%)
BABA   72.42 (+1.16%)
T   17.63 (+0.46%)
F   13.18 (+0.92%)
MU   117.93 (-1.02%)
CGC   9.77 (+2.30%)
GE   175.15 (-2.76%)
DIS   122.66 (+1.39%)
AMC   3.69 (-14.98%)
PFE   27.98 (+0.72%)
PYPL   67.18 (+0.92%)
XOM   115.84 (+0.76%)
S&P 500   5,249.49 (+0.02%)
DOW   39,753.43 (-0.02%)
QQQ   444.26 (-0.13%)
AAPL   171.28 (-1.17%)
MSFT   420.06 (-0.33%)
META   486.26 (-1.54%)
GOOGL   150.72 (-0.10%)
AMZN   180.14 (+0.17%)
TSLA   177.42 (-1.34%)
NVDA   905.75 (+0.36%)
NIO   4.57 (-2.14%)
AMD   180.85 (+0.70%)
BABA   72.42 (+1.16%)
T   17.63 (+0.46%)
F   13.18 (+0.92%)
MU   117.93 (-1.02%)
CGC   9.77 (+2.30%)
GE   175.15 (-2.76%)
DIS   122.66 (+1.39%)
AMC   3.69 (-14.98%)
PFE   27.98 (+0.72%)
PYPL   67.18 (+0.92%)
XOM   115.84 (+0.76%)
S&P 500   5,249.49 (+0.02%)
DOW   39,753.43 (-0.02%)
QQQ   444.26 (-0.13%)
AAPL   171.28 (-1.17%)
MSFT   420.06 (-0.33%)
META   486.26 (-1.54%)
GOOGL   150.72 (-0.10%)
AMZN   180.14 (+0.17%)
TSLA   177.42 (-1.34%)
NVDA   905.75 (+0.36%)
NIO   4.57 (-2.14%)
AMD   180.85 (+0.70%)
BABA   72.42 (+1.16%)
T   17.63 (+0.46%)
F   13.18 (+0.92%)
MU   117.93 (-1.02%)
CGC   9.77 (+2.30%)
GE   175.15 (-2.76%)
DIS   122.66 (+1.39%)
AMC   3.69 (-14.98%)
PFE   27.98 (+0.72%)
PYPL   67.18 (+0.92%)
XOM   115.84 (+0.76%)
S&P 500   5,249.49 (+0.02%)
DOW   39,753.43 (-0.02%)
QQQ   444.26 (-0.13%)
AAPL   171.28 (-1.17%)
MSFT   420.06 (-0.33%)
META   486.26 (-1.54%)
GOOGL   150.72 (-0.10%)
AMZN   180.14 (+0.17%)
TSLA   177.42 (-1.34%)
NVDA   905.75 (+0.36%)
NIO   4.57 (-2.14%)
AMD   180.85 (+0.70%)
BABA   72.42 (+1.16%)
T   17.63 (+0.46%)
F   13.18 (+0.92%)
MU   117.93 (-1.02%)
CGC   9.77 (+2.30%)
GE   175.15 (-2.76%)
DIS   122.66 (+1.39%)
AMC   3.69 (-14.98%)
PFE   27.98 (+0.72%)
PYPL   67.18 (+0.92%)
XOM   115.84 (+0.76%)
NASDAQ:DRRX

DURECT (DRRX) Stock Price, News & Analysis

$1.25
-0.10 (-7.09%)
(As of 12:54 PM ET)
Today's Range
$1.17
$1.30
50-Day Range
$0.71
$1.37
52-Week Range
$0.47
$7.46
Volume
175,312 shs
Average Volume
207,400 shs
Market Capitalization
$37.14 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$35.00

DURECT MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
2,723.7% Upside
$35.00 Price Target
Short Interest
Healthy
3.72% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.19
Upright™ Environmental Score
News Sentiment
0.10mentions of DURECT in the last 14 days
Based on 10 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.46) to ($1.24) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.77 out of 5 stars

Medical Sector

259th out of 939 stocks

Pharmaceutical Preparations Industry

114th out of 433 stocks

DRRX stock logo

About DURECT Stock (NASDAQ:DRRX)

DURECT Corporation, a biopharmaceutical company, researches and develops medicines based on its epigenetic regulator and pharmaceutical programs. The company offers ALZET product line that consists of osmotic pumps and accessories used for research in mice, rats, and other laboratory animals. It also develops larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis. In addition, the company offers POSIMIR, a post-surgical pain product to deliver bupivacaine over three days in adults; and Methydur to treat attention deficit hyperactivity disorder. It markets and sells its ALZET lines through direct sales force in the United States, as well as through a network of distributors in Japan, Europe, and internationally. The company has strategic collaboration and other agreements with Virginia Commonwealth University Intellectual Property Foundation; Indivior UK Ltd.; and Innocoll Pharmaceuticals Limited. DURECT Corporation was incorporated in 1998 and is headquartered in Cupertino, California.

DRRX Stock Price History

DRRX Stock News Headlines

Durect: Q4 Earnings Insights
DURECT Corp. Q4 Loss decreases, beats estimates
Top Project Outperforms BTC in 2023…
According to a recently published report… One DeFi protocol boasted gains over 100% during one of the biggest crashes the crypto market has ever seen. And now, this crypto coin is set to soar in the parabolic bull run projected in 2024.
DURECT Q4 2023 Earnings Preview
DURECT (DRRX) to Release Earnings on Wednesday
Top Project Outperforms BTC in 2023…
According to a recently published report… One DeFi protocol boasted gains over 100% during one of the biggest crashes the crypto market has ever seen. And now, this crypto coin is set to soar in the parabolic bull run projected in 2024.
DURECT Co. (NASDAQ:DRRX) Short Interest Up 6.6% in February
DURECT (NASDAQ:DRRX) Downgraded by StockNews.com to "Sell"
DRRX Apr 2024 5.000 call
DRRX Apr 2024 0.500 put
DRRX Mar 2024 1.500 put
DURECT: Reading Into AHFIRM Mortality Rates
Recap: Durect Q3 Earnings
Durect Corp DRRX
4DRRX : Durect Earnings Preview
See More Headlines
Receive DRRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for DURECT and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/01/2021
Today
3/28/2024
Next Earnings (Estimated)
5/13/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:DRRX
Employees
72
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$35.00
High Stock Price Target
$41.00
Low Stock Price Target
$27.00
Potential Upside/Downside
+2,723.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
4 Analysts

Profitability

Net Income
$-35,330,000.00
Net Margins
-398.65%
Pretax Margin
-398.65%

Debt

Sales & Book Value

Annual Sales
$19.28 million
Book Value
$1.10 per share

Miscellaneous

Free Float
28,546,000
Market Cap
$36.97 million
Optionable
Optionable
Beta
0.82
12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

  • Dr. James E. Brown D.V.M. (Age 67)
    Co-Founder, CEO, President & Director
    Comp: $885.86k
  • Ms. Judy R. Joice (Age 67)
    Senior Vice President of Operations & Corporate Quality Assurance
    Comp: $451.82k
  • Dr. Norman L. Sussman M.D. (Age 71)
    Chief Medical Officer
    Comp: $587.95k
  • Mr. Timothy M. Papp M.B.A. (Age 48)
    CFO & Secretary
  • Ms. Jian Li M.B.A. (Age 54)
    Interim Principal Accounting Officer, Senior VP of Finance, Corporate Controller & Secretary
    Comp: $297.08k
  • Dr. WeiQi Lin M.D.
    Ph.D., Executive VP of Research & Development and Principal Scientist
  • Mr. Keith L. Lui M.B.A.
    Senior Vice President of Business Development, Commercial & Medical Affairs
  • Dr. Su Il Yum Ph.D. (Age 85)
    Executive Officer
    Comp: $331.74k

DRRX Stock Analysis - Frequently Asked Questions

Should I buy or sell DURECT stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for DURECT in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" DRRX shares.
View DRRX analyst ratings
or view top-rated stocks.

What is DURECT's stock price target for 2024?

4 analysts have issued 12-month price targets for DURECT's shares. Their DRRX share price targets range from $27.00 to $41.00. On average, they predict the company's share price to reach $35.00 in the next twelve months. This suggests a possible upside of 2,723.7% from the stock's current price.
View analysts price targets for DRRX
or view top-rated stocks among Wall Street analysts.

How have DRRX shares performed in 2024?

DURECT's stock was trading at $0.59 at the beginning of the year. Since then, DRRX stock has increased by 110.1% and is now trading at $1.2395.
View the best growth stocks for 2024 here
.

When is DURECT's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 13th 2024.
View our DRRX earnings forecast
.

How were DURECT's earnings last quarter?

DURECT Co. (NASDAQ:DRRX) posted its quarterly earnings results on Monday, November, 1st. The specialty pharmaceutical company reported ($0.40) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.50) by $0.10. The specialty pharmaceutical company had revenue of $2.17 million for the quarter, compared to analysts' expectations of $2.18 million. DURECT had a negative trailing twelve-month return on equity of 289.99% and a negative net margin of 398.65%. During the same period last year, the company earned ($0.50) EPS.

When did DURECT's stock split?

DURECT shares reverse split on Tuesday, December 6th 2022. The 1-10 reverse split was announced on Tuesday, December 6th 2022. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, December 6th 2022. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What other stocks do shareholders of DURECT own?

Based on aggregate information from My MarketBeat watchlists, some companies that other DURECT investors own include Geron (GERN), Catalyst Pharmaceuticals (CPRX), VBI Vaccines (VBIV), MannKind (MNKD), Novavax (NVAX), Cassava Sciences (SAVA), Amarin (AMRN), Matinas BioPharma (MTNB), Inovio Pharmaceuticals (INO) and Verastem (VSTM).

Who are DURECT's major shareholders?

DURECT's stock is owned by a number of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (3.60%), Vanguard Group Inc. (3.60%), Richmond Brothers Inc. (1.74%), Silverberg Bernstein Capital Management LLC (0.16%), Virtu Financial LLC (0.15%) and Barclays PLC (0.00%). Insiders that own company stock include Gail J Maderis, Gail M Farfel, Judith J Robertson, Judy R Joice, Mohammad Azab and Simon X Benito.
View institutional ownership trends
.

How do I buy shares of DURECT?

Shares of DRRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:DRRX) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners